CVS Group plc - Full year trading update
For Immediate Release 23 July 2026
CVS Group plc
("CVS", the "Company" or the "Group")
Full year trading update
FY26 Adjusted EBITDA3 in line with market consensus
Continued growth in the Australian market
CVS, the UK listed veterinary group and a leading provider of veterinary services is pleased to issue the following update on trading for the financial year ended
CVS expects to announce its FY26 preliminary results on
FY26 Highlights1
· Full year revenue growth of 5.9% to
· Australia revenue increased
· The Group expects to report FY26 Adjusted EBITDA3 of approximately
· Adjusted EBITDA3 margin has been maintained at 19.9% for the full year (FY25: 20.0%), within our stated guidance of 19% to 23%.
· Expansion in Australia continues, with six practice acquisitions7 (comprising 14 practice sites) in the year in addition to buying out a minority interest, for an aggregate initial consideration of
· The Group continues to adopt a disciplined approach to capital expenditure, investing
· Net bank borrowings5 increased to
· As announced on
Acquisitions:
Australia
The Group has increased its presence in Australia, successfully building on its established platform, completing six acquisitions of small animal first opinion practices comprising 14 practice sites in the financial year in addition to buying out a minority interest, for initial consideration, net of cash acquired of
The Group now operates across 35 practices, comprising 57 practice sites. The Board is pleased with the performance in Australia, with the practices collectively performing ahead of the Group's business plans, partly driven by buying synergies.
The Group has also exchanged contracts on two further practice acquisitions in South Australia, comprising four sites, for an initial consideration of approximately
Competition and Markets Authority ('CMA')
The Group welcomes the certainty following the publication by the CMA of its Final Decision on
CEO succession
Further to the announcement on
Capital allocation and returns webcast
The Group is hosting an investor presentation at 14.00 BST today, where the Group will provide a more detailed update on its capital allocation priorities as well as more information on past and anticipated returns from its investments. To access a live streaming of the event, please click on the following link https://brrmedia.news/CVS_2026. A recording of the webcast alongside the presentation will be available on the Company's website https://www.cvsukltd.co.uk/investor-centre/ following the event.
Outlook
The Group has a strong balance sheet and free cash flows to support its capital allocation priorities. The pipeline of acquisition opportunities in Australia remains strong, and the Board is confident in returning to accretive acquisitions in the UK, at appropriate multiples.
The economic backdrop in the UK remains challenging with low consumer confidence impacting footfall in companion animal practices. However, with the expansion in Australia progressing well, the UK CMA process drawing to an end, and the structurally favourable dynamics of the sector, CVS remains well positioned to deliver attractive growth in shareholder value over the medium and long-term.
The Board reiterates its thanks to CVS colleagues for their contribution over the past financial year and looks forward to delivering further growth in the year ahead.
Richard Fairman, Chief Executive Officer commented:
"I am pleased that, despite the challenging UK economic backdrop, we delivered further growth in revenue and earnings.
"Our Australia practices continue to perform well and we have increased our market share through accretive acquisitions. Australia now represents around 11 per cent of Group revenue, with acquisitions performing ahead of plan and benefiting from buying synergies. We have a strong pipeline of further acquisition opportunities in Australia.
"With the CMA process now concluded, our
Notes:
1. Numbers included are unaudited
2. Like-for-like sales shows revenue generated from continuing like-for-like operations compared to the prior year, adjusted for the number of working days and on a constant currency basis. For example, for a practice acquired in
3. Adjusted EBITDA is calculated by reference to profit before tax for continuing operations, adjusted for interest (net finance expense), depreciation, profit or loss on disposal of property, plant and equipment, amortisation, costs relating to business combinations and exceptional items. Adjusted EBITDA is an alternative performance measure and is defined in the APM glossary of the 2025 Annual Report. Adjusted EBITDA margin is Adjusted EBITDA dividend by revenue
4. The company compiled consensus range and averages for FY26 adjusted EBITDA of
5. Net bank borrowings is drawn bank debt less cash and cash equivalents
6. Leverage on a bank test basis is net bank borrowings divided by Adjusted EBITDA3, annualised for the effect of acquisitions, adding back share option costs, on an accounting basis prior to the adoption of IFRS 16
7. FY26 Practices Acquired:
|
Practice name |
% acquired |
Date of acquisition |
|
Toorak Road Vet Clinic & Caulfield Veterinary Hospital |
100% |
|
|
Sydney Animal Hospital incorporating: Avalon Vet Pty Ltd, Sydney Animal Hospitals - Northern Beaches Pty Ltd, Inner West Veterinary Hospital Pty Ltd, Sydney Animal Hospitals Pty Ltd, Sydney Animal Hospitals - Norwest Pty Ltd AND Sydney Animal Hospitals - Kellyville Pty Ltd |
75% |
|
|
Sydney Animal Hospital incorporating: Baulkham Hill Pty Ltd |
75% |
|
|
Highview Vets Pty Ltd t/a Austinmer Veterinary Hospital & Helensburgh Veterinary Clinic |
100% |
|
|
PPAH Vets Pty Ltd t/a Port Phillip Animal Hospital |
100% |
|
|
Pittwater Animal Hospital Pty Ltd |
100% |
|
|
Animal Medical Centre Veterinary Hospital Pty Ltd |
65% |
|
|
Contacts CVS Group plc Richard Fairman, Chief Executive Officer Robin Alfonso, Chief Financial Officer Paul Higgs, Chief Veterinary Officer Charlotte Page, Head of Investor Relations
|
via FGS Global |
|
FGS Global Faeth Birch Charlie Chichester Hannah Ratcliff |
+44 (0)207 251 3801 |
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.
The Group operates over 480 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").
The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE